Clinical Trials
5 trialsNCT01258998 2020-11-04
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01481129 2017-09-28
Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01369849 2017-09-15
Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01466868 2014-07-10
AKTIL
Centre Leon Berard
Phase 2 Terminated
NCT01231919 2014-04-29
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
National Cancer Institute (NCI)
Phase 1 Completed